Regeneron Pharmaceuticals (NASDAQ: REGN) — Perfil da empresa, notícias e dados financeiros
Regeneron Pharmaceuticals develops innovative medicines for serious diseases, driven by a strong R&D pipeline.
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious medical conditions. The company focuses on biopharmaceutical product development across several major therapeutic areas, including eye diseases, allergic and inflammatory conditions, oncology, hematology, cardiovascular and metabolic disorders, rare diseases, and infectious diseases. Utilizing proprietary technology platforms such as humanized monoclonal antibody development systems and large-scale genetic sequencing facilities, the business advances pipeline candidates from early laboratory discovery through global clinical trials and commercial distribution. Its operational capabilities encompass integrated research laboratories, international manufacturing plants, and clinical development organizations worldwide.
Resumo
Operações
Produtos e/ou serviços de Regeneron Pharmaceuticals
- Ophthalmology Care: Biologic treatments for retinal conditions such as wet age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion. High-dose vascular endothelial growth factor inhibitor formulations are distributed globally across major ophthalmic health centers.
- Immunology Therapeutics: Monoclonal antibodies targeting interleukin-4 and interleukin-13 pathways for chronic inflammatory conditions, including moderate-to-severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, and eosinophilic esophagitis across adult and pediatric markets globally.
- Oncology and Immuno-Oncology: Programmed death-1 receptor blocking antibodies and T-cell engaging bispecific antibodies developed for solid tumors, cutaneous squamous cell carcinoma, basal cell carcinoma, and hematologic malignancies, administered through specialized oncology networks internationally.
- Cardiovascular and Metabolic Therapies: Monoclonal antibody treatments designed to lower low-density lipoprotein cholesterol and target lipid disorders, including proprotein convertase subtilisin/kexin type 9 inhibitors for patients with heterozygous and homozygous familial hypercholesterolemia worldwide.
- Rare Disease Treatments: Targeted biologic therapies for rare genetic disorders and ultra-rare inflammatory conditions, including interleukin-1 receptor antagonists and angiopoietin-like 3 inhibitors supplied to specialized tertiary hospitals and research medical centers globally.
- Genomics and Drug Discovery: Integrated biotechnology platforms and genomic research centers conducting large-scale DNA sequencing to identify novel disease targets, supporting a pipeline of approximately 50 clinical-stage drug candidates across multiple therapeutic areas worldwide.
equipe executiva do Regeneron Pharmaceuticals
- Leonard S. SchleiferCo-Founder, President, CEO & Co-Chairman
- George D. YancopoulosCo-Founder, President, Chief Scientific Officer & Co-Chairman
- Christopher R. FenimoreExecutive VP of Finance & CFO
- Joseph J. LaRosaExecutive VP, General Counsel & Secretary
- Andrew J. MurphyExecutive VP of Research & Co-Chief Scientific Officer
- Daniel P. Van PlewExecutive VP and GM of Industrial Operations & Product Supply
- Rajesh AhujaSenior Vice President of Quality Assurance & Operations
- Ryan SteinbergerExecutive VP, Chief Digital & Technology Officer
- Ryan CroweSenior Vice President of Investor Relations & Strategic Analysis
- Melissa LoznerSenior VP & Chief Compliance Officer
Últimas notícias sobre a Regeneron Pharmaceuticals
Regeneron closes Q3 with 36% revenue growth to $5.12 billion
United StatesRegeneron expands Ebola supply agreement by $270 million
United StatesRegeneron seeks six-week Libtayo dosing across EU indications
United StatesRegeneron expands Sanofi antibody alliance
United StatesRegeneron revenue advances to $4.29B as growth accelerates
United StatesRepligen in discussions to buy BioLife in $1.5 billion deal
United States
Histórico de dividendos
Dividendos por ação pagos pela Regeneron Pharmaceuticals, por ano fiscal.
| Ano fiscal | Intermediário | Final | Especial | Total |
|---|---|---|---|---|
| FY2026(até o momento) | — | — | — | $3.7600 |
| FY2025 | — | — | — | $3.5200 |
Principais indicadores financeiros
Resultados divulgados pela Regeneron Pharmaceuticals, em USD.
- Cap. de mercado
- 95,2 bi
- Receita (TTM)
- 16,9 bi
- P/L
- 20.3
- LPA (diluído, TTM)
- 45.2
- Dividend yield
- 0.4%
- Margem de lucro
- 28.5%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 14,3 bi | 3,6 bi | 4,5 bi | |
| 14,2 bi | 4 bi | 4,4 bi | |
| 13,1 bi | 4 bi | 4 bi | |
| 12,2 bi | 5,4 bi | 4,3 bi |